UBS upgraded Medacta Group to Buy from Neutral with a price target of CHF 137, up from CHF 119. Medacta’s unique focus on niche segments has driven 3-5x orthopedic growth and this should continue in 2024-2024, warranting a 35%-40% premium to the sector, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>